Trial Profile

A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Dostarlimab (Primary) ; Mocertatug rezetecan (Primary) ; Carboplatin; Cisplatin
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms BEHOLD-2
Sponsors GlaxoSmithKline Research & Development; GSK

31 Aug 2026 Planned number of patients changed from 392 to 305.
22 May 2026 Planned End Date changed from 5 Apr 2028 to 10 Oct 2028.
22 May 2026 Planned primary completion date changed from 17 Dec 2027 to 21 Jun 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com